retatrutide efficacy weight loss phase 2 trial results Looking forward to when # retatrutide's 3 will become available Eli Lilly's retatrutide shows promising

Model and physiological RS 2 and RSSR substrates are, for example, bis(2-hydroxyethyl)disulfide (HEDS) 1,3,12,14,30 , l-cystine 1,3 , redox-sensitive yellow or green fluorescent protein 2 (rxYFP or roGFP2) 14,15,31,32,33,34,35 , insulin 36,37 , collapsin response mediator protein 2 38,39 , the transcription factor OxyR 40 , 3-phosphoadenosine 5-phosphosulfate reductase (PR) 41,42 , methionine sulfoxide reductase (MSR) 34,43,44 , and ribonucleotide reductase (RNR) 2,34,45,46,47

The published Phase 2 trial evaluated 1 mg, 4 mg, 8 mg, and 12 mg groups with different starting-dose approaches, and gastrointestinal events were dose-related

Body weight and food intake were recorded daily, and animals were euthanized 24 hours after the final dose for biochemical and tissue analyses [2]

This figure indicates a reasonably good correlation between TOCC and SOCC for the three studied IDYs